Article

Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma

Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, 1428 Buenos Aires, Argentina.
Journal of Experimental Medicine (Impact Factor: 13.91). 10/2012; 209(11):1985-2000. DOI: 10.1084/jem.20111665

ABSTRACT Kaposi’s sarcoma (KS), a multifocal vascular neoplasm linked to human herpesvirus-8 (HHV-8/KS-associated herpesvirus [KSHV])
infection, is the most common AIDS-associated malignancy. Clinical management of KS has proven to be challenging because of
its prevalence in immunosuppressed patients and its unique vascular and inflammatory nature that is sustained by viral and
host-derived paracrine-acting factors primarily released under hypoxic conditions. We show that interactions between the regulatory
lectin galectin-1 (Gal-1) and specific target N-glycans link tumor hypoxia to neovascularization as part of the pathogenesis
of KS. Expression of Gal-1 is found to be a hallmark of human KS but not other vascular pathologies and is directly induced
by both KSHV and hypoxia. Interestingly, hypoxia induced Gal-1 through mechanisms that are independent of hypoxia-inducible
factor (HIF) 1α and HIF-2α but involved reactive oxygen species–dependent activation of the transcription factor nuclear factor
κB. Targeted disruption of Gal-1–N-glycan interactions eliminated hypoxia-driven angiogenesis and suppressed tumorigenesis
in vivo. Therapeutic administration of a Gal-1–specific neutralizing mAb attenuated abnormal angiogenesis and promoted tumor
regression in mice bearing established KS tumors. Given the active search for HIF-independent mechanisms that serve to couple
tumor hypoxia to pathological angiogenesis, our findings provide novel opportunities not only for treating KS patients but
also for understanding and managing a variety of solid tumors.

Download full-text

Full-text

Available from: Marta A Toscano, Jun 30, 2015
1 Follower
 · 
160 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the second most common cause of cancer and the sixth leading cause of cancer death among men worldwide. While localized prostate cancer can be cured, advanced and metastatic prostate cancer remains a significant therapeutic challenge. Malignant transformation is associated with important modifications of the cellular glycosylation profile, and it is postulated that these changes have a considerable relevance for tumor biology. Metastasis is a multiphasic process that encompasses angiogenesis, the spread of tumor cells and their growth at distant sites from the primary tumor location. Recognition of glycoconjugates by galectins, amongst other lectins, plays a fundamental role in the metastatic spread, tumor immune escape and the neovascularization process. Particularly in prostate cancer, both carbohydrates and galectins have been implicated in many cellular processes such as proliferation, apoptosis, migration and invasion. However, a limited number of studies assessed their potential implications in the induction of metastasis in prostate cancer patients or in animal models. Moreover, the role of galectin-glycan interactions in vivo still remains poorly understood; concerted effort should thus be made in order to shed some light on this question. This review summarizes current evidence on both the expression and role of glycans and galectins in prostate cancer, particularly turning our attention to the angiogenic and metastatic processes.
    Glycobiology 06/2014; 24(10). DOI:10.1093/glycob/cwu055 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Under normal conditions, platelets do not interact with blood vessel walls; however, upon activation, platelets firmly attach to endothelial cells. Communication between platelets and endothelial cells during the normal or activated state takes place at multiple levels. Cross-talk may occur over a distance via transient interactions or through receptor-mediated cell-cell adhesion. Platelets may release or transfer substances that affect endothelial cell function and vice versa. Excessive dialogue between platelets and the endothelium exists in several disease states as a causative factor and/or as a consequence of the disease process. Glycans are covalent assemblies of sugars that exist in either free form or in covalent complexes with proteins or lipids. Among other functions, glycans confer stability to the proteins to which they are attached, play key roles in signal transduction and control cell development and differentiation. Glycans not only influence the structure and function of haemostatic molecules but are also increasingly recognised as key molecules regulating platelet-endothelial interactions. The present review outlines the current knowledge regarding glycan-mediated interactions between platelets and endothelial cells and their role in physiopathological processes.
    Glycobiology 06/2014; 24(12). DOI:10.1093/glycob/cwu056 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The growth of new blood vessels out of the pre-existing vasculature, i.e. angiogenesis, is executed by endothelial cells that normally form the inner lining of blood vessels. During angiogenesis these cells exert different activities which require interactions with other cells and with the extracellular environment. It has become evident that this frequently involves galectins since the members of this protein family facilitate interactions betweens cells and/or glycoproteins via carbohydrate-binding. In addition, they can regulate intracellular processes like signaling and splicing via non-carbohydrate interactions. We have previously reported on the role of galectin-1 and galectin-9 in endothelial cell function. Here we review the current knowledge of these two galectins in endothelial cell biology and angiogenesis. In addition, we describe the contribution of both galectins to other processes that involve the endothelium, including inflammation and coagulation. Finally, we discuss the challenges for future research in order to better understand how this 'sweet' couple exerts its multifunctional activities within the vasculature.
    Glycobiology 05/2014; 24(10). DOI:10.1093/glycob/cwu048 · 3.75 Impact Factor